Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sunitinib in combination with erlotinib in advanced/metastatic non-small cell lung cancer
2007-001915-52Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Sutent + erlotinib with Placebo + erlotinib (2 arms). Primary endpoint: Overall Survival. Started Jun 2007; status: terminated.
02
Drugs
sunitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-001915-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001915-52.